News | May 13, 2021
Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
